Invitae Announces Final Medicare Pricing Set at $925 for Hereditary Breast Cancer-Related Disorders Under New Billing Process
“We applaud this historic transition by
The payments reflect a decision by the Palmetto MolDX program, the
Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s belief that Medicare’s new pricing makes genetic testing more affordable and accessible for patients with hereditary breast cancer related disorders; and that Medicare’s new, improved set of policies apply to all next-generation DNA sequencing assays for breast and ovarian cancer and will result in significant healthcare savings while improving patient care. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: that
About
NOTE:
View source version on businesswire.com: http://www.businesswire.com/news/home/20161003005505/en/
Laura D’Angelo, 314-920-0617
[email protected]
Source:
Combine Solicitation – Cost per test
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News